GCTK - closed +70% in AHs session (uber Nano-cap) PR: Glucotrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Tow
GCTK - closed +70% in AHs session (uber Nano-cap) PR: Glucotrack's Subsidiary, Lōkahi Therapeutics, Advances LT-100 Development Strategy Toward Single-Injection Administration; FDA Type C Meeting and Nonclinical Study Advance Strategy To Transition LT-100 From 15 Injections To One
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.